CVD - Sector: Healthcare --- Industry: Biotechnology & Drugs

[setravis]

Breakout from Symmetrical Triangle pattern.
Is it ready to make some waves to the upside?

News Link:   http://finance.yahoo.com/q/h?s=CVD

*************************************************************************
BUSINESS SUMMARY  
Covance, Inc. operates as a drug development services company. It offers a range of early stage and late stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries worldwide. The company also offers laboratory testing services to the chemical, agrochemical, and food industries. Covance offers a range of early development services, including preclinical and Phase I clinical service offerings that involve toxicology services, pharmaceutical chemistry, and bioanalytical and related services. Its late-stage development services include central laboratory services, clinical development services, periapproval services, central electrocardiogram diagnostic services, and healthcare economic and reimbursement services. Covance was founded in 1987 and is headquartered in Princeton, New Jersey.

[Melf Elf]

Breakout from Symmetrical Triangle pattern.
Is it ready to my some waves to the upside?

Looks good, and niice volume, too!  Applause.  Lots of breakouts lately.  That would seem to bode well for the market, in general, as long as down days result in successful re-tests of the breakouts, and not the false breakouts that we were seeing in some stocks for awhile.  Like that darned ECIL, which now looks like it could head higher again if it closes above $8.55.  I stopped it out for a 4% loss at just about the print low for stock 

[nikao]

nice chart.. i will watch this one and see if it will test the breackout.. will buy if the support holds

[setravis]

Put on a show.

[setravis]

Hmmmmm........

Technicals
Record Price High

Last Price Quote is:
3.13%above 13-day EMA
7.85%above 50-day EMA
RS Rating: 84 

Fundamentals
Key Data:
Market Cap (M): $3,778.10 
P/E Ratio: 31.95 
PEG Ratio: 1.47283 
Next Earnings: 04/19/2006
Last Analyst Rating: Buy

[setravis]

Today's closing chart.......

"The Golden Cross" has taken place...

52wk Range: 55.87 - 68.52
Volume: 562,300
Avg Vol (3m): 352,917

Technicals
Close Above the 13-day MA

Last Price Quote is:
2.66%above 13-day MA
4.92%above 50-day MA
RS Rating: 79 

Fundamentals
Key Data:
Market Cap (M): $4,162.15 
P/E Ratio: 28.23 
PEG Ratio: 1.54321 
Next Earnings: 07/23/2007
Last Analyst Rating: Outperform

[setravis]

Covance Inc (NYSE: CVD)
What a Company, wow what a chart !....Strong like superman...
Very few Biotechs can handle all their own services "in house" and Covance is cleaning-up by hiring skilled personell from downsized Biotech Firms and servicing a large majority of the Biotech Startups. This company is generating revenues to the tune of 1.5B+ with profit margins and growth consistently over 10%...Biotech companies come and go, but Covance will be around for for decades...
Oh, and can you say, NO DEBT! 


52wk Range: 57.12 - 84.26
Volume: 412,500
Avg Vol (3m): 369,336
Market Cap: 5.41B
P/E (ttm): 33.55
EPS (ttm): 2.52

Technicals
Record Price High
Record Price Break Out

RS Rating: 90 

Fundamentals
Key Data:
Market Cap (M): $5,267.68 
P/E Ratio: 32.71 
PEG Ratio: 1.7027 
Next Earnings: 01/23/2008
Last Analyst Rating: Equal-Weight


Below are the 6 month, 1 year, 2 year and 3 year charts.......

[setravis]

PRINCETON, N.J., Nov 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- Covance Inc. (CVD, Trade) announced today the purchase of a partially constructed manufacturing facility located on a 47-acre property in Prince William County's Technology Park from Eli Lilly. The company intends to transform the current facility into a 410,000-square-foot state-of-the-art early drug development laboratory offering safety testing and chemistry analysis services.

"The increased demand from our biopharmaceutical clients for our preclinical safety service offerings has led Covance to seek opportunities to enhance and expand our operations in Northern Virginia and build upon our multi-year global expansion plans," said Wendel Barr, Covance Senior Vice President and President of Early Development North America. "For 60 years, Covance operations in Northern Virginia have made significant contributions to the development of new medicines for HIV/AIDS, breast cancer, heart disease, leukemia, diabetes, Alzheimer's, multiple sclerosis, cystic fibrosis, deadly infections, and many other debilitating diseases. With our long history in the area, we are looking forward to continuing our relationships as a member of the community as well as contributing to the diversification of the local economy."

Covance plans to relocate approximately 450 current employees from its existing operations in Vienna, Va. and Chantilly, Va. to this facility by 2011, and hire an additional 100 employees by the year 2014. The total planned investment for this project is approximately $175 million. Covance expects to receive approximately $3.7 million in combined financial incentives from the Commonwealth of Virginia and Prince William County.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with revenues over the last twelve months of approximately $1.5 billion, global operations in more than 20 countries, and approximately 8,700 employees worldwide. Information on products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.

SOURCE Covance Inc.

http://www.covance.com 

Copyright (C) 2007 PR Newswire. All rights reserved

[setravis]

PRINCETON, N.J., April 3, 2008, 2008 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with its first quarter 2008 earnings release (expected to be issued after market close on April 28), Covance Inc. (CVD, Trade) is pleased to invite you to listen to its quarterly investor conference call which will be broadcast live over the Internet on Tuesday, April 29 at 9:00 a.m. ET.


 
    What:   Covance First Quarter 2008 Earnings Webcast and Slide Presentation 
    When:   April 29, 2008, 9:00 a.m. ET* 
    Where:  http://www.covance.com 

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,700 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.

*If you are unable to participate during the live webcast, the event will be archived on the web site http://www.covance.com for 14 days.

SOURCE Covance Inc.



http://www.covance.com 

Copyright (C) 2008 PR Newswire. All rights reserved

[setravis]

Covance Inc (NYSE: CVD)
What a Company, wow what a chart !....Strong like superman...
Very few Biotechs can handle all their own services "in house" and Covance is cleaning-up by hiring skilled personell from downsized Biotech Firms and servicing a large majority of the Biotech Startups. This company is generating revenues to the tune of 1.5B+ with profit margins and growth consistently over 10%...Biotech companies come and go, but Covance will be around for for decades...
Oh, and can you say, NO DEBT! 

52wk Range: 59.50 - 96.81
Volume: 279,013
Avg Vol (3m): 619,851
Market Cap: 5.52B
P/E (ttm): 31.72
EPS (ttm): 2.71

Technicals
Last Price Quote is:
0.48%above 13-day MA
1.71%above 50-day MA
RS Rating: 33 

Fundamentals
Key Data:
Market Cap (M): $5,447.95 
P/E Ratio: 31.78 
PEG Ratio: 1.46774 
Next Earnings: 04/28/2008
Last Analyst Rating: Buy